Alethia Young
Stock Analyst at Cantor Fitzgerald
(4.82)
# 102
Out of 4,433 analysts
100
Total ratings
61.86%
Success rate
49.3%
Average return
Main Sectors:
36 Stocks
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| REGN Regeneron Pharmaceuticals | Maintains: Neutral | $800 → $850 | $978.21 | -13.11% | 7 | Oct 16, 2023 | |
| RCUS Arcus Biosciences | Reiterates: Overweight | $46 | $17.55 | +162.11% | 4 | Sep 12, 2023 | |
| ALXO ALX Oncology Holdings | Reiterates: Overweight | $18 | $15.02 | +19.84% | 6 | Sep 12, 2023 | |
| CRIS Curis | Reiterates: Overweight | $60 | $13.00 | +361.54% | 3 | Sep 7, 2023 | |
| LBPH Longboard Pharmaceuticals | Reiterates: Overweight | $16 | $21.14 | -24.31% | 5 | Aug 22, 2023 | |
| ELDN Eledon Pharmaceuticals | Reiterates: Overweight | $9 | $2.51 | +259.28% | 2 | Aug 22, 2023 | |
| ARWR Arrowhead Pharmaceuticals | Maintains: Overweight | $79 → $47 | $25.04 | +87.70% | 3 | Aug 8, 2023 | |
| VSTM Verastem | Reiterates: Overweight | $34 | $13.12 | +159.15% | 2 | Jul 6, 2023 | |
| NEXI NexImmune | Downgrades: Neutral | n/a | $3.47 | - | 2 | Nov 16, 2022 | |
| BIIB Biogen | Maintains: Neutral | n/a | $235.32 | - | 4 | Oct 15, 2021 | |
| ADVM Adverum Biotechnologies | Downgrades: Neutral | $230 → $30 | $8.75 | +242.86% | 4 | Jul 23, 2021 | |
| RAPT RAPT Therapeutics | Maintains: Overweight | n/a | $4.25 | - | 1 | Jun 14, 2021 | |
| VRTX Vertex Pharmaceuticals | Maintains: Overweight | n/a | $437.49 | - | 3 | Jun 11, 2021 | |
| AKBA Akebia Therapeutics | Initiates: Overweight | n/a | $1.18 | - | 1 | Mar 8, 2021 | |
| FATE Fate Therapeutics | Maintains: Overweight | n/a | $4.24 | - | 1 | Feb 25, 2021 | |
| AMGN Amgen | Maintains: Overweight | n/a | $319.04 | - | 6 | Feb 3, 2021 | |
| BCYC Bicycle Therapeutics | Initiates: Overweight | n/a | $22.36 | - | 1 | Oct 12, 2020 | |
| GILD Gilead Sciences | Maintains: Overweight | n/a | $67.01 | - | 2 | Aug 19, 2020 | |
| TGTX TG Therapeutics | Maintains: Overweight | n/a | $17.72 | - | 1 | May 6, 2020 | |
| MRNS Marinus Pharmaceuticals | Reiterates: Overweight | n/a | $1.33 | - | 1 | May 5, 2020 | |
| ASND Ascendis Pharma | Reiterates: Overweight | n/a | $124.04 | - | 5 | Apr 20, 2020 | |
| PTCT PTC Therapeutics | Reiterates: Overweight | n/a | $33.66 | - | 3 | Apr 8, 2020 | |
| PACB Pacific Biosciences of California | Assumes: Overweight | n/a | $2.15 | - | 1 | Mar 9, 2020 | |
| AUPH Aurinia Pharmaceuticals | Maintains: Overweight | n/a | $5.31 | - | 1 | Mar 6, 2020 | |
| SRPT Sarepta Therapeutics | Reiterates: Overweight | n/a | $132.50 | - | 7 | Feb 27, 2020 | |
| AGIO Agios Pharmaceuticals | Reiterates: Overweight | n/a | $35.18 | - | 4 | Feb 14, 2020 | |
| INCY Incyte | Maintains: Neutral | n/a | $57.05 | - | 2 | Jan 3, 2020 | |
| ANAB AnaptysBio | Initiates: Outperform | n/a | $25.60 | - | 2 | Jul 19, 2018 | |
| MESO Mesoblast | Downgrades: Underperform | n/a | $7.20 | - | 3 | Mar 22, 2018 | |
| ALNY Alnylam Pharmaceuticals | Maintains: Outperform | n/a | $147.40 | - | 3 | Mar 13, 2018 | |
| BMRN BioMarin Pharmaceutical | Maintains: Outperform | n/a | $80.40 | - | 2 | Mar 2, 2018 | |
| PBYI Puma Biotechnology | Maintains: Outperform | n/a | $4.65 | - | 4 | Jan 24, 2018 | |
| NTLA Intellia Therapeutics | Maintains: Outperform | n/a | $26.22 | - | 1 | Nov 3, 2017 | |
| DRI Darden Restaurants | Maintains: Neutral | n/a | $151.78 | - | 1 | Sep 27, 2017 | |
| UTHR United Therapeutics | Initiates: Underperform | n/a | $272.69 | - | 1 | Mar 16, 2017 | |
| ACIU AC Immune | Initiates: Outperform | n/a | $3.51 | - | 1 | Oct 18, 2016 |
Regeneron Pharmaceuticals
Oct 16, 2023
Maintains: Neutral
Price Target: $800 → $850
Current: $978.21
Upside: -13.11%
Arcus Biosciences
Sep 12, 2023
Reiterates: Overweight
Price Target: $46
Current: $17.55
Upside: +162.11%
ALX Oncology Holdings
Sep 12, 2023
Reiterates: Overweight
Price Target: $18
Current: $15.02
Upside: +19.84%
Curis
Sep 7, 2023
Reiterates: Overweight
Price Target: $60
Current: $13.00
Upside: +361.54%
Longboard Pharmaceuticals
Aug 22, 2023
Reiterates: Overweight
Price Target: $16
Current: $21.14
Upside: -24.31%
Eledon Pharmaceuticals
Aug 22, 2023
Reiterates: Overweight
Price Target: $9
Current: $2.51
Upside: +259.28%
Arrowhead Pharmaceuticals
Aug 8, 2023
Maintains: Overweight
Price Target: $79 → $47
Current: $25.04
Upside: +87.70%
Verastem
Jul 6, 2023
Reiterates: Overweight
Price Target: $34
Current: $13.12
Upside: +159.15%
NexImmune
Nov 16, 2022
Downgrades: Neutral
Price Target: n/a
Current: $3.47
Upside: -
Biogen
Oct 15, 2021
Maintains: Neutral
Price Target: n/a
Current: $235.32
Upside: -
Adverum Biotechnologies
Jul 23, 2021
Downgrades: Neutral
Price Target: $230 → $30
Current: $8.75
Upside: +242.86%
RAPT Therapeutics
Jun 14, 2021
Maintains: Overweight
Price Target: n/a
Current: $4.25
Upside: -
Vertex Pharmaceuticals
Jun 11, 2021
Maintains: Overweight
Price Target: n/a
Current: $437.49
Upside: -
Akebia Therapeutics
Mar 8, 2021
Initiates: Overweight
Price Target: n/a
Current: $1.18
Upside: -
Fate Therapeutics
Feb 25, 2021
Maintains: Overweight
Price Target: n/a
Current: $4.24
Upside: -
Amgen
Feb 3, 2021
Maintains: Overweight
Price Target: n/a
Current: $319.04
Upside: -
Bicycle Therapeutics
Oct 12, 2020
Initiates: Overweight
Price Target: n/a
Current: $22.36
Upside: -
Gilead Sciences
Aug 19, 2020
Maintains: Overweight
Price Target: n/a
Current: $67.01
Upside: -
TG Therapeutics
May 6, 2020
Maintains: Overweight
Price Target: n/a
Current: $17.72
Upside: -
Marinus Pharmaceuticals
May 5, 2020
Reiterates: Overweight
Price Target: n/a
Current: $1.33
Upside: -
Ascendis Pharma
Apr 20, 2020
Reiterates: Overweight
Price Target: n/a
Current: $124.04
Upside: -
PTC Therapeutics
Apr 8, 2020
Reiterates: Overweight
Price Target: n/a
Current: $33.66
Upside: -
Pacific Biosciences of California
Mar 9, 2020
Assumes: Overweight
Price Target: n/a
Current: $2.15
Upside: -
Aurinia Pharmaceuticals
Mar 6, 2020
Maintains: Overweight
Price Target: n/a
Current: $5.31
Upside: -
Sarepta Therapeutics
Feb 27, 2020
Reiterates: Overweight
Price Target: n/a
Current: $132.50
Upside: -
Agios Pharmaceuticals
Feb 14, 2020
Reiterates: Overweight
Price Target: n/a
Current: $35.18
Upside: -
Incyte
Jan 3, 2020
Maintains: Neutral
Price Target: n/a
Current: $57.05
Upside: -
AnaptysBio
Jul 19, 2018
Initiates: Outperform
Price Target: n/a
Current: $25.60
Upside: -
Mesoblast
Mar 22, 2018
Downgrades: Underperform
Price Target: n/a
Current: $7.20
Upside: -
Alnylam Pharmaceuticals
Mar 13, 2018
Maintains: Outperform
Price Target: n/a
Current: $147.40
Upside: -
BioMarin Pharmaceutical
Mar 2, 2018
Maintains: Outperform
Price Target: n/a
Current: $80.40
Upside: -
Puma Biotechnology
Jan 24, 2018
Maintains: Outperform
Price Target: n/a
Current: $4.65
Upside: -
Intellia Therapeutics
Nov 3, 2017
Maintains: Outperform
Price Target: n/a
Current: $26.22
Upside: -
Darden Restaurants
Sep 27, 2017
Maintains: Neutral
Price Target: n/a
Current: $151.78
Upside: -
United Therapeutics
Mar 16, 2017
Initiates: Underperform
Price Target: n/a
Current: $272.69
Upside: -
AC Immune
Oct 18, 2016
Initiates: Outperform
Price Target: n/a
Current: $3.51
Upside: -